GAITHERSBURG, MD, March 14, 2022 (GLOBE NEWSWIRE) -- NexImmune, Inc. (Nasdaq: NEXI), a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targeted immune response by directing the function of antigen-specific T cells, today announced a research and evaluation collaboration with The Laura and Isaac Perlmutter Cancer Center, a National Cancer Institute designated Comprehensive Cancer Center and part of NYU Langone Health. The collaboration is centered around NexImmune’s artificial antigen presenting cells' (aAPCs) ability to expand neoantigen-specific CD8+ T cells in apheresis material provided by melanoma patients. Dr. Jeffrey S. Weber, Deputy Director of the Laura and Isaac Perlmutter Cancer Center will guide the research and evaluation.
“NexImmune is excited to have Dr. Weber and NYU, one of the nation’s leading academic cancer centers, as a partner on this collaboration,” said Kristi Jones, Chief Executive Officer of NexImmune. “The AIM technology platform offers a way to explore the expansion of neoantigens not only in melanoma, but a myriad of other cancers. This step will help validate our approach to these novel targets. Collaboration in this field will continue to help us deliver novel and impactful therapies to people suffering with cancer.”
“I look forward to working with NexImmune on this important work, with the goal of advancing these technologies and delivering next-generation immunotherapies to patients suffering with cancer,” stated Dr. Weber. “NexImmune’s platform has proven it can consistently expand antigen specific T cells for known tumor and viral antigens. This work could help us create T cell products that directly target disease specific neoantigens by utilizing the AIM platform.”
Further terms of this evaluation agreement have not been disclosed.
About NexImmune NexImmune is a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to employ the body’s own T cells to generate a specific, potent, and durable immune response. The backbone of NexImmune’s approach is a proprietary Artificial Immune Modulation (AIM™) nanoparticle technology platform. The AIM technology enables NexImmune to construct nanoparticles that function as synthetic dendritic cells capable of directing a specific T cell-mediated immune response. AIM constructed nanoparticles employ natural biology to engage, activate and expand endogenous T cells in ways that combine anti-tumor attributes of antigen-specific precision, potency and long-term persistence with reduced potential for off-target toxicities. NexImmune’s two lead programs, NEXI-001 and NEXI-002, are in Phase 1/2 clinical trials for the treatment of relapsed AML after allogeneic stem cell transplantation and multiple myeloma refractory to at least 3 prior lines of therapy, respectively. NexImmune is also developing new AIM nanoparticle constructs and modalities for potential clinical evaluation in oncology and in disease areas outside of oncology, including autoimmune disorders and infectious disease.
Dr. Jeffrey Weber is the Chair of NexImmune’s Scientific Advisory Board and receives compensation in connection with that role. These interests are managed according to NYU Langone Health policies and procedures. Questions regarding these interests may be directed to This email address is being protected from spambots. You need JavaScript enabled to view it. For more information, visit www.neximmune.com.
Forward Looking Statements This press release may contain “forward-looking” statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are based on the beliefs and assumptions and on information currently available to management of NexImmune, Inc. (the “Company”). All statements other than statements of historical fact contained in this press release are forward-looking statements, including statements concerning our planned and ongoing clinical studies for the Company’s product candidates, including NEXI-001 and NEXI-002; the initiation, enrollment, timing, progress, release of data from and results of those planned and ongoing clinical studies; and the utility of prior preclinical and clinical data in determining future clinical results. In some cases, you can identify forward-looking statements by terminology such as “may,” “will,” “should,” “expects,” “plans,” “anticipates,” “believes,” “estimates,” “predicts,” “potential” or “continue” or the negative of these terms or other comparable terminology. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the Company’s actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. These risks and uncertainties include, but are not limited to, the risks and uncertainties set forth in the “Risk Factors” section of our Annual Report on Form 10-K for the year ended December 31, 2020 filed with the Securities and Exchange Commission (“SEC”) on March 31, 2021, and subsequent reports that we file with the SEC. Forward-looking statements represent the Company’s beliefs and assumptions only as of the date of this press release. Although the Company believes that the expectations reflected in the forward-looking statements are reasonable, it cannot guarantee future results, levels of activity, performance or achievements. Except as required by law, the Company assumes no obligation to publicly update any forward-looking statements for any reason after the date of this press release to conform any of the forward-looking statements to actual results or to changes in its expectations.
Contacts
Investors: Chad Rubin, SVP Corporate Affairs NexImmune, Inc. 646.319.3261 This email address is being protected from spambots. You need JavaScript enabled to view it.